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Background and purpose of the study: Intractable seizures are a subgroup of epileptic disorders challenging the
physicians’ skills to become controlled. Showing resistance towards common pharmacotherapy, they demand
newer antiepileptic drugs acquired at higher costs. 0.06% of children around the world are estimated to suffer from
epilepsy and its consequences. The aim of the present study has been to evaluate the cost-effectiveness of these
drugs in the treatment of intractable seizures in children.
Methods: Clinical and cost data were collected from medical and cost records preserved at a neurologist office
and a referral pharmacy respectively. Based on the new AED which are accessible in Iran, regimens were
categorized into eight groups. The first group consisting of conventional AEDs was considered as comparator and
the effectiveness of other groups was compared with it. Incremental Cost-effectiveness Ratio (ICER) of adding-on
each new antiepileptic drug was calculated in terms of Rials per consequence (Rls/consq) and compared with each
other. Furthermore ICER of the regimens was compared with the GDP per capita (Gross Domestic Product) of the
year (2010).
Results: the ICER of the adding-on regimens range from negative values for Gabapentin, Levetiracetam and
Zonisamide to low values for Lamotrigine (~ 6.4 million Rials/consequence [mil Rls/consq]) and Oxcarbazepine
(~7.7 mil Rls/consq) and followed by high values for Topiramate (~21 mil Rls/consq) and Vigabatrin (~43.7 mil Rls/consq)
considering the three months of remaining on regimen. By increasing the limit of remaining time to six months,
the previously mentioned regimens persist on negative values. However Oxcarbazepine (~28.7 mil Rls/consq) and
Lamotrigine (~13.8 mil Rls/consq) show a steep increase. Topiramate (~23.6 mil Rls/consq) displays a less change.
Opposite to other regimens, the ICER value of Vigabatrin (~17.26 mil Rls/consq) has shown an important increase.
Major conclusions: Adding-on new antiepileptics to conventional regimens are cost-effective and justified
considering the GDP per capita.
Keywords: Cost-effectiveness, New antiepiletics, Intractable seizures, Children, Incremental cost-effectiveness ratioIntroduction
Epilepsy is defined as a neurological disorder of brain
portrayed by persisting predisposition to develop epilep-
tic seizures [1]. A proportion of 6 over 1,000 children
around the world are estimated to suffer from epilepsy
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distribution, and reproduction in any mediumconsequences [2]. Known as one of the most common
neurological disorders worldwide, epilepsy has several
treatment options. However pharmacotherapy remains
the mainstay [3]. Since 1993 a high increase in emerging
antiepileptic drugs (AEDs) has been observed [4]. The
Anatomical Therapeutic Chemical (ATC) classification
system of World Health Organization (WHO) collabor-
ating center identifies 45 medicinal substances used in
the treatment of epilepsy. Among which 13 are approved
and prescribed in Iran. A common style of classifying
AEDs is based on the year of introduction to the market.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,









Figure 1 Sample of model used to compare the effectiveness of adding-on Gabapentin to conventional regimen.
Gharibnaseri et al. DARU Journal of Pharmaceutical Sciences 2012, 20:17 Page 2 of 6
http://www.darujps.com/content/20/1/17In this perspective, AEDs fall into two categories. Con-
ventional AEDs including Carbamazepine, Ethosuximide,
Phenytoin, Phenobarbital, Primidone and Valproate and
the newer AEDs including Gabapentin, Levetiracetam,
Lamotrigine, Oxcarbazepine, Topiramate, Vigabatrin,
Zonisamide. It should be noticed that financial supports
are devoted to pharmaceuticals comprised in essential
drugs list of Iran [5], resulting in the high prescription of
them [6]. While the first generation of AEDs prescribed
as monotherapy shows promising results in almost 70%
of patients with epilepsy, polytherapy or adding-on newer
AEDs is demanded by the rest of the epileptic patients
whom are believed to meet intractable seizures [7].
In general, selecting an AED is performed on the
basis of many factors including relative efficacy, drug-
drug interactions, tolerability and cost [8]. The acquisi-
tion costs of newer AEDs are generally higher than the
older; nevertheless there superiority in controlling sei-
zures has to be established. Dealing with restricted
budget, clinicians and decision-makers are interested in
Pharmacoeconomics studies, which measure and bal-
ance costs and clinical outcomes of alternative medica-
tions. In spite of this, there is a tragic lack of literature
on this issue in Iran; however a few of them that have
been published in recent years could provide valuable
information for decision making [9]. Furthermore,
owing to the pharmacogenetics effect and the diversity
of genotypes, applying effectiveness data across different
countries is difficult [10].
The aim of this study was to compare cost-
effectiveness of newer AEDs being added to conventional
regimens in treating intractable seizures in children.
Methods
This study has been conducted in a cross sectional man-
ner. Clinical data was obtained from medical records of
patients archived at the office of a physician with well
established expertise in pediatric neurology. Patients
with seizures not being responsive to two or three con-
ventional AEDs were included in the study [11]. Cases
of nonepileptic seizures and misdiagnosis were excluded.
Regimens were categorized into eight groups. The first
group consisting in conventional AEDs was consideredaverage PDD ¼ dose 1 frequency of dose 1ð Þ þ doseð
frequency of dose 1þ frequas comparator and the effectiveness of other groups
were compared with it. Each of the new antiepileptic
drugs along with the regimen composed of conven-
tional AEDs was incorporated into a model resulting
in seven decision trees (sample shown in Figure 1).
An additional model comparing regimens composed
of conventional AEDs and any of the seven new AEDs
with the same assumptions mentioned above was set up
in order to evaluate the cost-effectiveness of adding-on
new AEDs in general (Figure 2).
Regarding the fact that either the inability of a regimen
in controlling seizures or the inappropriate safety profile
are the main reasons of switching the regimen by the clin-
ical specialist, thus remaining on a regimen has been
viewed as an acceptable indicator of effectiveness and
safety for regimens. Receiving approval by the clinician,
remaining on a regimen for three months and more was
regarded as effectiveness endpoint (desired consequence).
The proportion of seizure controlled patients to all the
patients incorporated into the model was assumed as the
effectiveness of the related regimen. The effectiveness of
regimens was calculated for both arms within each
model. Next the effectiveness of add-on regimens was
subtracted from the comparator’s regimen effectiveness.
ΔE ¼ Eaddon  Ecomparator
Cost data was primarily obtained from the referral
pharmacy of Tehran (Sizdah-e-Aban Pharmacy). Given
the perspective of our study has been that of the pa-
tients, latest sales price were collected and split in two
sets. The first set made up of the maximum prices con-
sisting of brand name drugs that at most cases are
imported and the second set comprised of the minimum
prices which belong to the generic drugs. As availability
of drugs has been the only determinant factor in pur-
chasing drugs, an average of these prices was computed.
Considering the variety of the dosage forms, standardiz-
ing the daily dose of each drug was necessary in order to
compare the cost of each regimen. This was managed by
calculating the prescribed daily dose (PDD) of each drug
as an average of all the existing doses reported in the
records.2 frequency of dose 2Þ









Figure 2 Decision tree of adding-on new AEDs to conventional regimens.
Table 1 Distribution of patients with intractable seizures
No. % of total
Sex Male 32 56.14
Female 25 43.86
Age 0–3 years 13 22.8
3–6 years 20 35.09
6–13 years 23 4.35
13–19 years 1 1.75
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day in two records and 600 mg/day in one record the
weighted average of PDD would equal 800 mg/day. PDD
of each AED was subsequently multiplied by the price of
1 mg of each drug -obtained by dividing the average
price by the potency of the dosage form- as well as
365 days of year for further comparison with the GDP
(Gross Domestic Product) per capita, resulting in the
cost of each regimen. The cost of the comparator group
(conventional AEDs) has not been calculated due to
being mentioned in both arms of the decision trees. In
other words the difference of costs of regimens (ΔC)
was simplified as followed:
ΔC ¼ CConventionalþnewAED  Cconventional ¼ CnewAED:
In order to compare the cost effectiveness of add-on





The final step was comparing the ICER of each new
AED as add-on therapy with the GDP per capita of Iran,
as a measure for assessing the cost-effectiveness of dif-
ferent regimens.
It should be noted that all costs are reported as Rials
(Rls) (1 United States of America’ Dollar (USD) ~ 10,000
Rls; 1 Euro ~ 15,000 Rls) in year 2010.
Sensitivity analysis was performed at three cost levels
(medium, average and maximum) and the model was re-
run with an effectiveness endpoint of six months.
Results
57 patients were approved with intractable seizures giv-
ing access to 284 records of regimens. The distribution
of patients has been depicted (Table 1).
ICERs regarding at least 3 months of maintenance
Table 2 shows the incremental cost-effectiveness ratio
of adding-on new AEDs in three months with average
prices, ranges from negative values for Gabapentin,
Levetiracetam and Zonisamide indicating them as domi-
nated regimens to positive values for Vigabatrin (ICER~43.7 mil Rls/consq), Topiramate (ICER~21 mil Rls/consq),
Oxcarbazepine (ICER~7.7 mil Rls/consq) and Lamotrigine
(ICER~6.3 mil Rls/consq).
ICERs regarding the overall effect of adding-on new AEDs
The incremental cost-effectiveness ratio of adding any of
the new AEDs shows a positive value of 37 million Rials
per a desired consequence. Changing the effectiveness
endpoint from three to six months raises the ICER value
to 42.4 mil Rls/consq (Table 3).
Comparison with GDP per capita
As depicted in Figure 3 all new AEDs excluding Levetir-
acetam, Gabapentin and Zonisamide fall under the GDP
per capita curve. It is noteworthy that Lamotrigine,
Oxcarbazepine and Topiramate keep a distance from the
curve while Vigabatrin and new AEDs point stand close
to the line.
Sensitivity analysis
Taking the case of two other price levels, can cause
changes in the ICER values (Figure 4). Increasing the
prices ends in falling the ICER of the new AEDs group
out of the very cost-effectiveness area (> GDP per
capita). Decreasing the prices, results in the enhance-
ment of cost-effectiveness of Topiramate comparing to
the GDP per capita level, followed by improvement of
the cost-effectiveness of the new AEDs.
Table 2 Cost-effectiveness comparison of newer AEDs in three months at average prices
Regimen ΔE ΔC ICER (Rials per consequence)
conventional AEDs+ Gabapentin −0.52 1525051 Dominated
conventional AEDs+ Lamotrigine 0.13 826145 6354964
conventional AEDs+ Levetiracetam −0.52 1732229 Dominated
conventional AEDs+ Oxcarbazepine 0.15 1149750 7665000
conventional AEDs+ Topiramate 0.36 7553771 20982698
conventional AEDs+ Vigabatrin 0.15 6560510 43736733
conventional AEDs+ Zonisamide −0.52 1445400 Dominated
Note: the regimen solely composed of old AEDs is assumed as the comparator regimen.
Table 3 Cost-effectiveness comparison of adding-on new
AEDs in three and six months at average prices
Endpoint ΔE ΔC (Rials) ICER
3 months 0.08 2970408 37130101
6 months 0.07 2970408 42434402
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tam and Zonisamide still show negative values. Oxcarba-
zepine (ICER~28.7 mil Rls/consq) turns out to exhibit
dramatic changes in the cost-effectiveness due to striking
decrease in effectiveness, followed by Topiramate (ICER~
23.6 mil Rls/consq). The increase for Lamotrigine (ICER~
13.8 mil Rls/consq) has been less considerable. Opposite
to the previous regimens Vigabatrin (ICER~17.3 mil Rls/
consq) has shown a substantial decrease.
Discussion
The results confirm that adding-on new AEDs to con-
ventional regimens in controlling intractable seizures inFigure 3 Cost-effectiveness analysis; Comparison of the ICER of addinchildren is cost-effective comparing to regimens com-
posed entirely of conventional AEDs. However choosing
certain AEDs added to the conventional regimen espe-
cially in long term requires extra consideration. Given the
general advantages of monotherapy against polytherapy,
physicians’ preference could be driven towards mono-
therapy by cost-effective regimens including newer AEDs
such as Oxcarbazepine, Lamotrigine and Topiramate.
Since the value that Iranian society recognize for
health outcomes is unknown, interpreting the results ex-
press complicacy [13]. WHO guidelines recommend
comparing the cost-effective ratio (CER) with the GDP
per capita of the country [14]. The GDP per capita of
Iran reported by the International monetary fund (2010)
has been US$ 4400 [15] (~ 44 mil Rls). It should be
noted that changes in any factor that modify the calcu-
lated costs such as exchange rates, prices and etc. can
result in a different cost-effectiveness comparison. There
lays a vast difference between these amounts and theg-on new AEDs with the GDP per capita level.
Figure 4 ICER sensitivity analysis at different price levels and
different clinical endpoints.
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of the newer AEDs in large numbers. In spite of this, by
considering the six months of retention as the desirable
consequence, the ICER values of Oxcarbazepine at three
price levels and Topiramate at the maximum price ex-
ceed the GDP per capita levels requiring more observa-
tion on their prescription. This is due to noticeable
decrease in the efficacy of regimen.
If a specific regimen is causative of unacceptable side
effects or is not efficient, the patient would have been
quickly switched to an alternative regimen. Therefore re-
tention rates of different regimens are appropriate indi-
ces for effectiveness. In addition actual clinical data used
in this study instead of receiving abstract information by
clinicians, improves realization of the results. While the
study has much strength, cost and medical databanks
not being available accounts for limitations through the
study.
Collecting clinical data from a referral but single cen-
ter can be responsible for undesirable bias in the results.
Indirect costs such as costs pertaining to side effects and
clinical visits were not included in this economic evalu-
ation and different types of epilepsy were not separated
due to the low number of patients.
Our results are quite different from Frew’s study that
has demonstrated the newer and older antiepileptic
drugs different in cost terms while equal in efficacy term
[16]. This conflict arises from the different target group.
Similarly, Knoester’s and Connek’s studies confirmed the
use of older AEDs for patients newly diagnosed epilepsy
while not included refractory patients [2,17]. Some stud-
ies such as Boon et al. have shown the favorableness of
surgery in refractory patients compared with conserva-
tive treatment [18]. In general due to methodological
issues comparing different studies is not always possible[19] and using standardized approach is suggested for
further researches.
Conclusion
Adding-on new antiepileptics to conventional regimens
is cost-effective and justified considering the GDP per
capita. Among the new adding-on AEDs prescribed in
Iran, Lamotrigine shows the best results in terms of
cost-effectiveness in treating children with intractable
seizures. As the same, Oxcarbazepine and Topiramate
fall under the GDP per capita level, while Vigabatrin
stands close to the standard. However, other adding-on
medications; Gabapentin, Levetiracetam and Zonisa-
mide; in treating the target population appears not to be
cost-effective due to less effectiveness compared with
older AEDs.
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